Upload
others
View
1
Download
0
Embed Size (px)
Citation preview
FRCPath Pancreas Course
A practical approach
Dr Tu Vinh Luong
Consultant Histopathologist
Wednesday 19th February 2020
Acknowledgments
Many images and tables in this presentation are from Dr Klimstra’s paper (Lab Med—Vol 133, March 2009)
and Dr Hornick’s (Brigham and Women’s Hospital, Harvard Medical School, Boston, MA) lecture
WHO 2019 Classification
Changes since 2010
• Precursors are now classified into two-tiered system of dysplasia:1. Low grade IPMN/mucinous cystic neoplasm/Pan-IN2. High grade IPMN/mucinous cystic neoplasm/Pan-IN
• Classification of pancreatic NENs• New subtype of ductal adenocarcinoma:
micropapillary carcinoma (aggressive clinical course)• Oncocytic-type IPMN is now recognised as a distinct
entity (IOPN)• The only emerging new entity is sclerosing epithelioid
mesenchymal tumour
Abridged classification of pancreatic epithelial neoplasms
ENTITY
• Ductal adenocarcinoma
• IPMN
• Pancreatic NET
• Serous cystadenoma
• Mucinous cystic neoplasm
• Acinar cell carcinoma
• Solid pseudopapillaryneoplasm
• Pancreatoblastoma
Pancreatic neoplasms, %
• 85
• 3-5
• 3-4
• 1-2
• 1-2
• 1-2
• 1-2
• <1
Diagnostic clues from the clinical presentation
• Age
• Sex
• Location
• Symptoms
Algorithm for the diagnostic evaluation of pancreatic neoplasm
Klimstra et al. Arch Pathol Lab Med—Vol 133, March 2009WHO 2010 Classification
First step – Diagnostic algorithmGross appearance
Klimstra et al. Arch Pathol Lab Med—Vol 133, March 2009
Algorithm for the diagnostic evaluation of pancreatic neoplasm
Klimstra et al. Arch Pathol Lab Med—Vol 133, March 2009
Solid neoplasmsNature of epithelium and stroma
<< epithelium / >>stroma >> epithelium / << stroma
Klimstra et al. Arch Pathol Lab Med—Vol 133, March 2009
Ductal adenocarcinoma
Solid neoplasmsPredominant cellular differentiation
Klimstra et al. Arch Pathol Lab Med—Vol 133, March 2009
Acinar cell carcinoma Neuroendocrine neoplasm
Acinar neuroendocrine undetermined
Pancreatoblastoma Solid pseudopapillaryneoplasm
Squamoid nests
yes no
IMMUNOHISTOCHEMISTRY IN THE DIFFERENTIAL DIAGNOSIS OF SOLID CELLULAR PANCREATIC TUMORS
MarkerPoorly Differentiated
Ductal AdenocarcinomaAcinar Cell Carcinoma
PancreatoblastomaPancreatic Endocrine
Tumor
Solid Pseudopapillary
Tumor
Keratin + + + + Rare cells
Chromogranin −Scattered
cellsFocal + −
Synaptophysin −Scattered
cellsFocal + Scattered cells
Trypsin/chymotrypsin − + + − −
Nuclear beta-catenin − SubsetFocal (squamoid
corpuscles)− +
Loss of DPC4 + − − − −
PNET vs PSN
PNET PSN
Algorithm for the diagnostic evaluation of pancreatic neoplasm
Klimstra et al. Arch Pathol Lab Med—Vol 133, March 2009
Cystic neoplasms
? Degenerative changes ? Truly cystic, lined by epithelium
Solid pseudopapillaryneoplasm
Pseudocyst
Cystic lesions of the pancreas
? Degenerative changesTruly cystic, lined by epithelium
Solid pseudopapillaryneoplasm
Pseudocyst
Cystic change in typically solid tumours:- Ductal adenocarcinoma- Cystic pancreatic NET- Cystic acinar neoplasms
Cystic neoplasmsTruly cystic-epithelium lined
Serous
Subepithelial stroma/Relationship to ducts
Serous cystadenoma Mucinous cysticneoplasm
IPMN
Cellular stroma/Separate from ducts
No cellular stroma/Connected to ducts
Mucinous
Serous cystic neoplasms
• Serous cystic neoplasms are the most common type of true cystic neoplasms of the pancreas
• Most serous tumours of the pancreas are benign.• Only rare cases metastasize (serous
cystadenocarcinoma).• Malignancy is defined as metastasis: in the absence of
demonstrable metastases, any typical serous neoplasm should be considered benign.
• ICD-O Code: – Serous cystadenoma 8441/0– Serous cystadenocarccinoma 8441/3
Serous cystadenoma
• Serous cystadenomas arise mostly (50-75%) in the body or tail of the pancreas
• Occur predominantly in women (female-to-male ratio of 3 : 1).
• The mean age of patients at diagnosis is 58 years.
• As many as 90% of patients with VHL syndrome develop serous cystic neoplasms
Serous cystadenoma
The lesion is well circumscribed and composed of small cysts measuring less than 1 cm in the greatest dimension and separated by thin, translucent septa. The innumerable cysts produce a gross appearance resembling that of a sponge.A central, stellate, fibrous scar can be seen.
Serous cystic neoplasm
A. At low power, innumerable small cysts are seen. Each small cyst is lined by a flattened layer of epithelium.
B. At higher power, cytologically, the lining cells show clear cytoplasm and small, uniform, hyperchromatic nuclei. The cells are arranged in a single, flat layer without nuclear atypia
Serous cystic neoplasm
• Histologically and immunophenotypically, all types of serous neoplasms appear to recapitulate centroacinar cells.
• For instance, they express low-molecular-weight keratins, EMA, inhibin, and Melan-A (MART1).
• Molecular genetic alterations include mutations of the von Hippel-Lindau tumour suppressor gene (VHL on chromosome 3p25.3) and allelic losses on chromosome 10q.
• Genetic abnormalities typical of ductal adenocarcinoma (e.g., mutations of KRAS and TP53) have not been identified in serous tumours nor have mutations in GNAS or RNF43, which are found in other cystic or intraductal pancreatic neoplasms
Mucinous cystic neoplasms
• Similar to their serous counterparts, mucinous cystic neoplasms are true cystic neoplasms of the pancreas.
• They are seen almost exclusively in women (with rare examples documented in men; F:M ratio of 20:1) in the fifth to sixth decades of life (mean age, 50 years).
• Patients with MCNs with an associated invasive carcinoma are 5-10 years older, on average, than are patients with non invasive MCNs.
• The tumour usually (>95%) is located in the body and tail of the pancreas.
• Presenting symptoms are nonspecific and are usually the result of the effects of an enlarging mass.
Mucinous cystic neoplasms
• ICD-O-Code:• MCN with low-grade dysplasia 8470/0
• MCN with high-grade dysplasia 8470/2
• MCN with associated invasive
carcinoma 8470/3
• Terms that are no longer to be used:
– Mucinous cystadenoma NOS (not otherwise specified)
– Mucinous cystadenocarcinoma, NOS
Mucinous cystic neoplasm
Distal pancreatectomy showing a circumscribed tumour containing numerous, large (1- to 5-cm) cysts. The septa are fibrotic and show no gross evidence of solid tumour nodules in this example. The cyst contents are often mucoid, but some may have a watery consistency.
Mucinous cystic neoplasm
At low power, the mucinous cysticneoplasm is surrounded by a thick, fibrouscapsule. The large cysts are lined bymucinous epithelium, and the stroma ofthe septa is hypercellular.
At higher magnification, the epitheliallining is composed of tall, columnar,mucin-containing cells. In this region,there is low-grade dysplasia. Thesubepithelial stroma is hypercellular,resembling the stroma of the ovary.
Mucinous cystic neoplasm with an associated invasive carcinoma
(mucinous cystadenocarcinoma)
• Invasive carcinoma may develop in mucinous cystic neoplasms
• Invasive carcinoma arising in a mucinous cystic neoplasm usually resembles conventional pancreatic ductal adenocarcinoma.
• However, other types, such as sarcomatoid carcinoma, or undifferentiated carcinoma with osteoclast-like giant cells, may occur
• Overall, the rate of malignancy in mucinous cystic neoplasms is approximately 10%
• Staging is based on the size of the invasive component
Mucinous cystic neoplasms
• Molecular analysis has disclosed mutations or promoter methylation in many of the genes known to be abnormal in ductal adenocarcinomas, including KRAS, TP53, SMAD4, and CDKN2A.
• Approximately one half of mucinous cystic neoplasms have mutations in RNF43, which codes for a protein with intrinsic E3 ubiquitin ligase activity that is also mutated in IPMNs but not in ductal adenocarcinomas.
• GNAS mutations are not found in mucinous cystic neoplasms, in contrast to IPMNs.
IPMN
• Preoperative differentiation of an intraductalneoplasm from true cystic neoplasms, such as serous or mucinous cystic neoplasms, can be difficult
• Endoscopic findings (e.g., mucin extrusion through the ampulla of Vater) and radiographic findings (e.g., ectasia of the ducts) are diagnostic features.
• Approximately 80% of IPMNs occur in the head of the pancreas.
• Based on the extent of involvement of the ductal system, IPMNs are classified as main duct and branch duct types.
• Branch duct IPMNs may appear as multiple, separate, small cysts grossly and radiographically because of the tortuous nature of the dilated ducts.
• IPMNs are a precursor to and a marker of invasive carcinoma.
• Invasive carcinoma may occur in or distant from the intraductal component.
Intraductal neoplasms are typically cystic radiographically, but are epithelial neoplasms with ductal differentiation that characteristically grow primarily
within the ductal system of the pancreas.
IPMN
Gastric type Pancreatobiliary type Intestinal type
• Low-grade IPMN (previous low and intermediate-grade dysplasia)
• High-grade IPMN
Pancreatic intraductal oncocyticpapillary neoplasm
• Grossly IOPN is a cystic epithelial neoplasm and forms large friable projections or solid nodules within cystically dilated pancreatic ducts
• Microscopically, IOPN forms complex and arborising papillae, lined by 2-5 layers of cuboidal to columnar cells with mitochondrion-rich eosinophilicgranular cytoplasm that contains a large, round nucleus with a prominent nucleolus. Interspersed goblet cells are common. All IOPNs have high-grade dyslasia.
IMMUNOHISTOCHEMICAL PROFILE
Gastric type IPMN Pancreatobiliary type IPMN IOPNIntestinal type IPMN
CK7CK18
+ + + +
CK20 - - + + in goblet cells
MUC1 - + - +
MUC2 - - + + in goblet cells
MUC5AC + + + +
MUC6 -/+ + - +
CDX2 - - + + in goblet cells
CategoryPrevious terminology
and synonymsDescription
Normal Normal ductal and ductular epithelium cuboidal to low columnar.No mucinous cytoplasm, nuclear crowding, or atypia.
PanIN-1A Mucinous cell hyperplasia, mucinous ductal hyperplasia, simple hyperplasia, mucinous hypertrophy
Flat epithelial lesions composed of tall columnar cells with basal nuclei and abundant supranuclear mucin. Nuclei small and round.
PanIN-1B Papillary ductal hyperplasia,adenomatous hyperplasia
Epithelial lesions with papillary, micropapillary, or basally pseudostratified architecture, but otherwise identical to PanIN-1A.
PanIN-2 Adenomatous hyperplasia, atypical hyperplasia Usually papillary mucinous epithelial lesions with
some nuclear abnormalities, including loss of polarity, nuclear crowding, enlarged nuclei, pseudostratification, and hyperchromatism. Mitoses rare.No cribriform structures or luminal necrosis.
PanIN-3 Severe ductal dysplasia, atypical hyperplasia, carcinoma in situ
Usually papillary or micropapillary. Cribriforming, “budding off” of small clusters of epithelial cells into the lumen, or luminal necrosis all suggest PanIN-3. Characterized by loss of nuclear polarity, dystrophic goblet cells, mitoses (occasionally abnormal), nuclear irregularities, and prominent nucleoli.
PANCREATIC INTRAEPITHELIAL NEOPLASIA Pan-IN
Adapted from Hruban et al. Am J Surg Pathol. 2001;25:579-86.
Low grade
High grade
PANCREATIC Pan-IN vs IPMN
Feature PanIN IPMN
Usually clinically detected No Yes
Usually grossly visible No Yes
Usually grossly visible mucin No Yes
Usually well-formed papillae No Yes
MUC2 expression No Often
Loss of DPC4/SMAD4 30% in PanIN-3 Rare
Associated with invasive colloid carcinoma No Yes
Adapted from Hruban et al. Am J Surg Pathol. 2001;25:579-86.
TNM staging of pancreatic exocrine tumours (UICC TNM 8th ed)
UICC/AJCC 7th UICC/AJCC 8th
T1 Confined to pancreas, <2 cm Tumour 2 cm or less in greatest dimension T1a Tumour 0.5 cm or lessT1b Tumour >0.5 cm and no >1cmT1c Tumour >1 cm but no >2cm
T2 Confined to pancreas, >2 cm Tumour >2 cm but < 4 cm
T3 Peripancreatic spread, but without major vascular invasion
Tumour > 4 cm
T4 Invasion of major vessels (coeliac axis or superior mesenteric artery)
Tumour involves coeliac axis, superior mesenteric artery and/or common hepatic artery
N1 Regional LN mets Regional LN metsN1 Metastasis in 1 to 3N1 Metastasis in 4 or more
M1 Distant metastasis Distant metastasis• M1a Hepatic mets only• M1b Extrahepatic mets only• M1c Hepatic and extrahepatic mets
UPDATE ON Pan-NENS
Changes since previous edition
• Tumour classification - WHO 2010 and WHO 2017
• Tumour staging – UICC TNM 8 (2017)
WHO 2010 WHO 2017
UPDATE ON RCPATH DATASET
Revised dataset for histopathological reporting of neuroendocrine neoplasms of the GEP tract - 2019
Evolution in WHO terminology for Pan-NENs
WHO 1980 WHO 2000/2004 WHO 2010 WHO 2017
I. Carcinoid 1. Well-differentiatedendocrine tumour (WDET)
2. Well-differentiated endocrine carcinoma (WDEC)
1. NET G1
2. NET G2
• NET G1
• NET G2
• NET G3
II. Mucocarcinoid 3. Poorly-differentiated endocrine carcinoma/small cell carcinoma (PDEC)
3. NEC G3 (large cell or small cell NEC)
• NEC G3 (large cell or small cell NEC)
III. Mixed formscarcinoid-adenocarcinoma
4. Mixed exocrine-endocrine carcinoma (MEEC)
4. Mixed
adenoneuroendocrine
carcinoma (MANEC)
Mixed
neuroendocrine/non
neuroendocrine
neoplasm (MiNEN)
IV. Pseudotumourlesion
5. Tumour-like leisons (TLL) 5. Hyperplastic and preneoplastic lesions
Abolished preneoplastic
category, because PanNEN
precursor changes have not been
clearly identified in association
with sporadic neoplasms
Tumour type and differentiation
Regardless of the site there are three major tumour types:
• well-differentiated NETs
• poorly differentiated NECs
• Mixed tumours or MiNENs
Terminology
• NET is a well-differentiated epithelial neoplasm with morphological and immunohistochemical features of neuroendocrine differentiation
• NETs can be low-grade (G1), intermediate-grade (G2) or high-grade (G3) tumours
• NEC is a poorly differentiated epithelial neoplasm with morphological and immunohistochemical features of neuroendocrine differentiation
• NEC is, by definition, high grade (for this reason, the WHO 2019 classification proposed not to assign a grade to NECs, whereas previously all NECs were graded G3)
Terminology
• There is no ‘well-differentiated neuroendocrine carcinoma’ category
• The term ‘NEN’ encompasses all well-differentiated and poorly differentiated tumours of the neuroendocrine cells
• MiNEN is a mixed epithelial neoplasm in which a neuroendocrine component is combined with a non-neuroendocrine component, each of which is morphologically and immunohistochemically recognisable as a discrete component and constitutes ≥30% of the neoplasm.
MiNENMixed neuroendocrine-non neuroendocrine neoplasms
• New term MiNEN replaces previous term MANEC
• MiNENs may have a non-endocrine component other than adenocarcinoma (e.g. squamous cell carcinoma, acinar cell carcinoma)
• To qualify as MiNEN each component must have at least 30~%
• Usually both components are high grade (G3), but occasionally one of the two or both components may belong to the G1/G2 category. When the components are morphologically distinguishable, they should be individually graded, using the respective grading systems for each.
An adenocarcinoma showing scattered neuroendocrine cells, demonstrated using anti-chromogranin A antibody, cannot be classified as a MiNEN
WHO 2017 PanNEN classification and WHO 2010 Pan-NEN classification
WHO 2017 pancreatic-NEN Classification WHO 2010 GEP-NEN Classification
Well-differentiated NETs
• NET G1
• NET G2
• NET G3
Well-differentiated NETs
• NET G1
• NET G2
Poorly differentiated NECs
• NEC G3 (large cell or small cell NEC)
Poorly differentiated NECs
• NEC G3 (large cell or small cell NEC)
Mixed neuroendocrine-non neuroendocrine
neoplasm (MiNEN)
Mixed adenoneuroendocrine carcinoma
(MANEC)
Abolished category, because PanNEN precursor
changes have not been clearly identified in
association with sporadic neoplasms2
Hyperplastic and preneoplastic lesions
2017 WHO classification of pancreatic NENs
Classification/grade Ki-67 proliferation index Mitotic index
• Well-differentiated PanNENs: pancreatic neuroendocrine tumours (PanNETs)
PanNET G1 <3% <2
PanNET G2 3-20% 2-20
PanNET G3 >20% >20
• Poorly-differentiated PanNENs: pancreatic neuroendocrine carcinomas (PanNECs)
PanNEC (G3)Small cell typeLarge cell type
>20% >20
• Mixed neuroendocrine-non neuroendocrine neoplasm (MiNEN)
TUMOUR GRADING
New recommendations for reporting Ki67
• The Ki-67 is based on the evaluation of >= 500 cells
• Assess hotspots (areas with higher nuclear labelling)
• Round up or down to the nearest whole number
• If mitotic count and Ki67 are discordant, the final grade is determined based on whichever index (Ki-67 or mitotic) places the tumour in the highest grade category
• Manual counting using camera-captured, printed images is recommended instead of casual visual estimation or eyeballing.
Pancreatic NENS with a Ki-67-index >20%
NET G3 NEC G3
Differentiation Well-differentiated Poorly-differentiated
Ki-67 >20%, no defined upper limit, butusually <55%
>20%, usually >55%
Mutations MEN1, DAXX, ATRX p53, RB1
p53 Focal, weak positivity Diffuse, strong positivity
SSTR2A 3+ 2+/1+/- (80%)
NET G3 NEC G3
Pancreatic NENS with a Ki-67-index >20%
Günter Klöppel, 2016 IAP-ESP presentation
ENETS vs UICC 7th vs UICC 8th TNM of the pancreas
54
ENETS UICC/AJCC 7th UICC/AJCC 8th
T1 Confined to pancreas, <2 cm Confined to pancreas, <2 cm Confined to pancreas*, 2 cm or less
T2 Confined to pancreas, 2–4 cm Confined to pancreas, >2 cm Confined to pancreas *>2 cm but < 4 cm
T3 Confined to pancreas, >4 cm or invading duodenum or bile duct
Peripancreatic spread, but without major vascular invasion
Confined to pancreas*, > 4 cmor invading duodenum or bile duct
T4 Invasion of adjacent organs (stomach, spleen, colon, adrenal gland) or the wall of large vessels (celiac axis or superior mesenteric artery)
Invasion of major vessels (coeliac axis or superior mesenteric artery)
Tumour perforates visceral peritoneum (serosa) or invades other organs or adjacent structures
N1 Regional LN mets Regional LN mets Regional LN mets
M1 Distant metastasis Distant metastasis Distant metastasis• M1a Hepatic mets only• M1b Extrahepatic mets
only• M1c Hepatic and
extrahepatic mets
* Confined to the pancreas means there is no invasion of adjacent organs (stomach, spleen, colon, adrenal gland) or the wall of large vessels (celiac axis or the superior mesenteric artery). Extension of tumour into peripancreatic adipose tissue is NOT a basis for staging.
Exceptions to the simplified algorithmic scheme
• Rare neoplasms (undifferentiated carcinoma with osteoclasticlike giant cells, medullary carcinoma, intraductal tubular carcinoma,lymphoepithelial cyst …)
• Common neoplasms with unusual features(solid variant of serous cystadenoma, ductal adenocarcinoma and NETs with cystic changes…)
• Carcinoma with mixed differentiation(acinar-endocrine, ductal-endocrine, acinar-ductal…)
• Metastatic disease(lung, kidney, ovary, breast and melanoma)
Serous cystadenoma in communication with the pancreatic duct
Berman L. J Clin Gastroenterol. 2010 Jul;44(6)
PD
PD
FRCPath Pancreas Course
Frozen sections
Commonest indications for
intraoperative frozen section diagnosis
• Histological confirmation of a potentially
metastatic nodule in the liver, peritoneum or
a lymph node
• Histological confirmation of the primary
diagnosis
• Assessment of the presence or absence of
carcinoma at the pancreatic transection
margin,
• Assessment of the presence or absence of
carcinoma at the bile duct margin
Diagnostic challenges
• Distinction between a liver metastasis
and a bile duct hamartoma/adenoma
may prove problematic
• Distinction between pancreatitis and
adenocarcinoma in the pancreas may
also be difficult on frozen section,
because of cautery or freezing
artefacts, or the distortion and reactive
nuclear atypia in small residual ductules
in chronic pancreatitis
Chronic pancreatitis vs Adenocarcinoma
Low power
- Retention of lobular arrangement (circles): larger, dilated central ducts surrounded by smaller, round ductules. The interlobular stroma is denser than the intralobular stroma
-Disorganized ductal distribution /lack of a lobular configuration- Abnormal location (perineural, adjacent to a muscular vessel, “naked glands” in fat, within duodenal muscularis)
Chronic pancreatitis vs Adenocarcinoma
High power
- Limited nuclear size variation - Slight nuclear irregularity - Inconspicuous nucleoli - Hyperchromatism represents a frozen section artifact
- Anisonucleosis (more than 4-fold nuclear variation)- Necrotic glandular debris - Partial duct lumen - Infiltrating single cells - Glandular mitotic figures (arrows)
FEATURES FAVORING PANCREATIC DUCTAL ADENOCARCINOMAIN FROZEN SECTIONS AND BIOPSIES
Feature Benign Malignant
Lobular configuration of ducts + −
Haphazard distribution of ducts − +
Incomplete duct lumina − +
Single atypical cells in stroma − +
Nuclear size variation 4:1 − +
Large, irregular nucleoli − +
Necrotic luminal debris − +
Glandular mitoses − +
Perineural invasion − +
Glands in adipose tissue − +
VHL positivity + -
Maspin positivity − +
p53 positivity − +
Mesothelin positivity − +
Loss of DPC4/SMAD4 − +